Steven Cohen’s Spyre Therapeutics SYRE Stock Holding History

Steven Cohen’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-662,351	Closed	-$21.7M	–	4474
2025 Q4	$21.7M	Buy	+662,351	New	+$17.3M	0.02%	833
2021 Q3	–	Sell	-18,791	Closed	-$3.27M	–	1238
2021 Q2	$3.27M	Sell	18,791 -41,209	-69%	-$7.49M	0.01%	679
2021 Q1	$11.9M	Sell	60,000 -56,822	-49%	-$10.9M	0.06%	389
2020 Q4	$23M	Buy	+116,822	New	+$24.2M	0.11%	251
2018 Q4	–	Sell	-10,625	Closed	-$2.54M	–	1192
2018 Q3	$2.54M	Buy	+10,625	New	+$2.48M	0.01%	726

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Steven Cohen's SYRE Position: Q1 2026 in Review

Steven Cohen sold out of Spyre Therapeutics (SYRE) in Q1 2026, closing a stake of 662,351 shares — an estimated $21.7M sold.

Steven Cohen first reported a position in SYRE in Q3 2018 and held it in 5 quarters. The position peaked at $23M in Q4 2020. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

Steven Cohen reported no remaining Spyre Therapeutics position as of Q1 2026 after selling out during the quarter.
Steven Cohen sold 662,351 Spyre Therapeutics shares in Q1 2026, an estimated $21.7M.
Steven Cohen first reported a position in Spyre Therapeutics in Q3 2018 and held it in 5 quarters.
Steven Cohen's Spyre Therapeutics position peaked at $23M in Q4 2020.
197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.